R01 CA041233/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
1999	1
2000	1
2001	1
2002	1
2006	1
2007	1
2008	2
2009	8
2010	5
2011	8
2012	3
2013	4
2014	1
2015	1
2018	1
2021	0

1

Tumor angiogenesis.

Kerbel RS. Kerbel RS. N Engl J Med. 2008 May 8;358(19):2039-49. doi: 10.1056/NEJMra0706596. N Engl J Med. 2008. PMID: 18463380 Free PMC article. Review. No abstract available.

2

Reappraising antiangiogenic therapy for breast cancer.

Kerbel RS. Kerbel RS. Breast. 2011 Oct;20 Suppl 3(0 3):S56-60. doi: 10.1016/S0960-9776(11)70295-8. Breast. 2011. PMID: 22015294 Free PMC article. Review.

3

Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Francia G, et al. Nat Rev Cancer. 2011 Feb;11(2):135-41. doi: 10.1038/nrc3001. Nat Rev Cancer. 2011. PMID: 21258397 Free PMC article. Review.

4

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Ebos JM, Kerbel RS. Ebos JM, et al. Nat Rev Clin Oncol. 2011 Mar 1;8(4):210-21. doi: 10.1038/nrclinonc.2011.21. Nat Rev Clin Oncol. 2011. PMID: 21364524 Free PMC article. Review.

5

Drug rechallenge and treatment beyond progression--implications for drug resistance.

Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Kuczynski EA, et al. Nat Rev Clin Oncol. 2013 Oct;10(10):571-87. doi: 10.1038/nrclinonc.2013.158. Epub 2013 Sep 3. Nat Rev Clin Oncol. 2013. PMID: 23999218 Free PMC article. Review.

6

Preclinical approaches to study the biology and treatment of brain metastases.

Cruz-Muñoz W, Kerbel RS. Cruz-Muñoz W, et al. Semin Cancer Biol. 2011 Apr;21(2):123-30. doi: 10.1016/j.semcancer.2010.12.001. Epub 2010 Dec 13. Semin Cancer Biol. 2011. PMID: 21147227 Free PMC article. Review.

7

Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer.

Kerbel RS. Kerbel RS. Breast. 2009 Oct;18 Suppl 3(0 3):S41-7. doi: 10.1016/S0960-9776(09)70271-1. Breast. 2009. PMID: 19914541 Free PMC article. Review.

8

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Ebos JM, Lee CR, Kerbel RS. Ebos JM, et al. Clin Cancer Res. 2009 Aug 15;15(16):5020-5. doi: 10.1158/1078-0432.CCR-09-0095. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671869 Free PMC article. Review.

9

A Single Mutation Traps a Half-Sites Reactive Enzyme in Midstream, Explaining Asymmetry in Hydride Transfer.

Finer-Moore JS, Lee TT, Stroud RM. Finer-Moore JS, et al. Biochemistry. 2018 May 15;57(19):2786-2795. doi: 10.1021/acs.biochem.8b00176. Epub 2018 May 2. Biochemistry. 2018. PMID: 29717875 Free PMC article.

10

Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.

Kuczynski EA, Lee CR, Man S, Chen E, Kerbel RS. Kuczynski EA, et al. Cancer Res. 2015 Jun 15;75(12):2510-9. doi: 10.1158/0008-5472.CAN-14-3687. Epub 2015 Apr 23. Cancer Res. 2015. PMID: 25908587 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results